Zanubrutinib
Treatment for Chronic Lymphoid Leukemia
Typical Dosage: 160mg twice daily or 320mg once daily orally
Effectiveness
90%
Safety Score
48%
Clinical Trials
42
Participants
4.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
160mg twice daily or 320mg once daily orally
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
93%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$160,000
Monitoring:$5,000
Side Effect Mgmt:$4,000
Total Annual:$169,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,490/QALY
QALYs Gained
1.4
Outcome-Based Costs
Cost per Responder
$187,778
Cost per Remission
$845,000
Comparison vs Acalabrutinib
Cost Difference
$0/year
Same cost
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Zanubrutinib Outcomes
for Chronic Lymphoid Leukemia
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Remission Rate
+20%
Common Side Effects
Neutropenia
+28%
Upper Respiratory Tract Infection
+20%
Bruising
+17%
Diarrhea
+16%
Muscle pain
+15%
Active Clinical Trials
17 active trials recruiting for Zanubrutinib in Chronic Lymphoid Leukemia
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
NCT07671378RECRUITINGPHASE2
24 participants
INTERVENTIONAL
Nanjing, China
Started: Jun 1, 2026
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
NCT04515238ACTIVE NOT RECRUITINGPHASE2
42 participants
INTERVENTIONAL
Augsburg, Germany +10 more
Started: Oct 1, 2020
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06544785RECRUITINGPHASE2
106 participants
INTERVENTIONAL
Alicante, Spain +18 more
Started: Sep 2, 2024
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501ACTIVE NOT RECRUITINGPHASE2
94 participants
INTERVENTIONAL
Weston, United States +31 more
Started: Nov 14, 2024
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT07739459NOT YET RECRUITINGPHASE2
95 participants
INTERVENTIONAL
Lyon, France +16 more
Started: Dec 1, 2026
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
NCT07674810NOT YET RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Houston, United States
Started: Dec 31, 2026
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
NCT07003464NOT YET RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Changchun, China
Started: Jun 15, 2025
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
NCT06367374NOT YET RECRUITINGPHASE2
66 participants
INTERVENTIONAL
Started: May 30, 2024
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231RECRUITINGPHASE3
500 participants
INTERVENTIONAL
Duarte, United States +113 more
Started: Jan 22, 2026
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
NCT05650723ACTIVE NOT RECRUITINGPHASE2
50 participants
INTERVENTIONAL
New York, United States
Started: May 8, 2023
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
NCT03824483ACTIVE NOT RECRUITINGPHASE2
230 participants
INTERVENTIONAL
Evanston, United States +7 more
Started: Feb 22, 2019
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT04458610ACTIVE NOT RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Houston, United States
Started: May 26, 2020
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT06547944ACTIVE NOT RECRUITINGPHASE1
30 participants
INTERVENTIONAL
Tianjin, China
Started: Jan 1, 2024
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
NCT07271667RECRUITINGPHASE2
108 participants
INTERVENTIONAL
Miami Beach, United States +10 more
Started: Apr 23, 2026
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
NCT05168930RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Scarborough, United States +3 more
Started: Feb 18, 2022
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06520098RECRUITINGPHASE2
100 participants
INTERVENTIONAL
San Francisco, United States +3 more
Started: Oct 1, 2025
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
NCT06849713RECRUITINGPHASE2
80 participants
INTERVENTIONAL
Boston, United States +1 more
Started: May 16, 2025
Completed Clinical Trials
2 completed trials for Zanubrutinib in Chronic Lymphoid Leukemia
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT03734016COMPLETEDPHASE3
652 participants
INTERVENTIONAL
Little Rock, United States +114 more
Started: Nov 1, 2018
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT03206918COMPLETEDPHASE2
91 participants
INTERVENTIONAL
Beijing, China +10 more
Started: Mar 9, 2017
Showing 20 of 53 total trials